Shareholder Alert: Ademi LLP investigates whether Pardes Biosciences, Inc. has obtained a Fair Price in its transaction with MediPacific

MILWAUKEE, July 17, 2023 /PRNewswire/ -- Ademi LLP is investigating Pardes (Nasdaq: PRDS) for possible breaches of fiduciary duty and other violations of law in its transaction with MediPacific. 

Click here to learn how to join the action https://www.ademilaw.com/case/pardes-biosciences-inc or call Guri Ademi toll-free at 866-264-3995.  There is no cost or obligation to you.

In the transaction, Pardes shareholders will receive only a price per share of not less than $2.02 in cash and an additional cash amount of not more than $0.17 per share at closing plus the CVR representing the right to receive 80% of the net proceeds payable from any license or disposition of Pardes' programs and assets effected within five years of closing. The transaction agreement unreasonably limits competing bids for Pardes by imposing a significant penalty if Pardes accepts a superior bid. Pardes insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Pardes' board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Pardes common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/pardes-biosciences-inc.                       

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP                                                          
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP